Data as of Nov 21
| +0.22 / +3.91%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 15.75, with a high estimate of 25.00 and a low estimate of 13.00. The median estimate represents a +169.69% increase from the last price of 5.84.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.